RESET-BP: Effect of Reducing Sedentary Behavior on Blood Pressure

Sponsor
University of Pittsburgh (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03307343
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
300
1
2
64.9
4.6

Study Details

Study Description

Brief Summary

This is a 2-arm, 3-month randomized trial comparing a novel sedentary behavior intervention vs. control in working adults (n=300). The primary outcome is resting systolic blood pressure (SBP) at 3 months; secondary outcomes will be resting diastolic blood pressure (DBP), ambulatory blood pressure (ABP), and carotid-femoral pulse wave velocity (cfPWV). Also, best practice objective activity monitoring will be leveraged in the analysis of ABP to account for recent activity and posture and will inform adherence and dose-response relationships.We will also measure plasma renin activity and aldosterone as a potential mechanism of blood pressure reduction, and insulin and glucose as exploratory outcomes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Intervention
N/A

Detailed Description

Hypertension (HTN) is the most common major risk factor for cardiovascular disease (CVD), affecting 1 in 3 American adults. Also, nearly another 1 in 3 adults has prehypertension (preHTN). Moderate-to-vigorous intensity physical activity (MVPA) is known to decrease BP. Guidelines recommend 150 min/week of MVPA performed in continuous bouts of ≥10 min (i.e., bouted MVPA). Sedentary behavior (SED), defined as sitting or reclining with low energy expenditure, has gained attention as a highly prevalent and distinct behavior from MVPA that is independently associated with higher BP, arterial stiffness, CVD, and mortality. These data, coupled with the fact that Americans spend more than half of the waking day in SED, suggest SED as a novel intervention target. Yet, despite heightened public perception of SED as a health risk, there is a dearth of randomized clinical trials demonstrating that SED reduction will lead to health benefits, including reduced BP. Decreasing SED more substantially could improve BP, but this remains unclear in the absence of larger randomized trials with effective SED interventions.

Thus, to test initial efficacy, the Effect of Reducing Sedentary Behavior on Blood Pressure (RESET-BP) has the following specific aims:

Specific aim 1: To evaluate the efficacy of our intervention targeting decreased sedentary behavior (SED) over 3 months. Outcomes include SBP (primary), DBP, ABP (nocturnal, daytime seated, daytime non-seated), and cfPWV. We hypothesize that the 3-month SED intervention will decrease SBP, DBP, ABP and cfPWV vs. controls

Specific Aim 2: To explore whether renin-angiotensin-aldosterone (RAAS) activation (increased plasma renin activity (PRA) and aldosterone) mediates changes in BP elicited by SED reduction

Specific Aim 3: To examine associations between achieved reductions in SED, increases in replacement behaviors (i.e., standing, other light-intensity physical activity (LPA), and BP reduction

These aims will be evaluated with a 2-arm, 3-month randomized trial comparing a novel SED intervention vs. control in 300 adults (150 per group). The study will recruit adults with untreated, elevated blood pressure (SBP 120-159 mmHg or DBP 80-99 mmHg) and desk jobs that require prolonged SED to maximize the opportunity for SED reduction. The intervention will target currently recommended levels of SED reduction for desk-based employees (2-4 hours/day with frequent postural changes) and will use a behavioral intervention including individual in-person (1/month) and phone counselling (1/month) focused on goal setting, overcoming barriers, self-monitoring, social support, and stimulus control. In addition, the intervention will include environmental modification via provision of a sit-stand desk attachment and external prompting via text messaging and a wrist-worn inactivity prompter.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcome assessors will be blinded to the participant group assignment.
Primary Purpose:
Treatment
Official Title:
Effect of Reducing Sedentary Behavior on Blood Pressure
Actual Study Start Date :
Jan 3, 2018
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

The intervention will use behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts to target a 2-4 hour/day reduction in sedentary behavior.

Behavioral: Intervention
The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
Other Names:
  • Sedentary Behavior Reduction
  • No Intervention: Control

    Participants randomized to the control condition will receive no intervention during the study. After the 3-month assessment, control participants will be provided with a wrist-worn activity monitor and will be offered the 3-month delayed intervention if desired to aid in retention and recruitment.

    Outcome Measures

    Primary Outcome Measures

    1. Resting Systolic Blood Pressure [3 months]

      Resting systolic blood pressure will be measured at baseline and follow-up using an oscillometric device after a 10-min rest on two occasions

    Secondary Outcome Measures

    1. 24-hour Ambulatory Blood Pressure [3 months]

      Ambulatory blood pressure will be measured at baseline and 3-month follow-up during a workday and overnight (24 hours total) at the beginning and end of the study.

    2. Pulse Wave Velocity [3 months]

      Carotid-femoral and carotid-radial pulse wave velocity will be measured at baseline and follow-up following a 10-min supine rest via tonometry.

    3. Plasma Renin Activity [3 months]

      PRA will be measured at baseline and 3-month follow-up.

    4. Aldosterone [3 months]

      Aldosterone will be measured at baseline and 3-month follow-up.

    5. Diastolic Blood Pressure [3 months]

      Resting diastolic blood pressure will be measured at baseline and follow-up using an oscillometric device after a 10-min rest on two occasions

    Other Outcome Measures

    1. Weight [3 months]

      Weight will be measured by digital scale at baseline and follow-up.

    2. Glucose [3 months]

      Glucose will be measured at baseline and follow-up.

    3. Insulin [3 months]

      Insulin will be measured at baseline and follow-up.

    4. Adverse Events [Adverse events will be measured in an ongoing fashion (as reported) and formally at the 3-month outcome assessment by blinded personnel in all participants.]

      We will compare adverse events between groups in the following two ways: 1) all reported events and 2) events reported at the 3-month outcome assessment. Because the increased contact with intervention participants (vs. no-contact control) could provide greater opportunity to report adverse events occurring over the 3-month study period, these two comparisons will help clarify associations between the intervention and adverse events.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age 21-65 years

    2. SBP 120-159 mmHg or DBP of 80-99

    3. Inactive (Engages in less than 150 min/wk of moderate + 2 x vigorous intensity physical activity)

    4. Currently perform deskwork for ≥ 20 hr/week at a desk compatible with the sit-stand attachment

    5. Employment within an approximate 25-mile radius of the University of Pittsburgh

    6. Stable employment (≥ 3 months in current job, plan to be in current job for the next 3 months)

    7. Supervisor approval to join the intervention

    8. Possession of a cellular phone able to receive text messages

    Exclusion Criteria:
    1. SBP ≥ 160 mmHg, DBP ≥ 100 mmHg

    2. Use of antihypertensive or glucose controlling medication

    3. Comorbid condition that would limit ability to reduce sedentary behavior (e.g. musculoskeletal condition, current chemotherapy)

    4. History of ischemic heart disease, chronic heart failure, stroke, or chronic kidney disease

    5. Unable to obtain consent from primary care provider or physician to participate

    6. Current use of sit-stand/standing desk, sedentary behavior prompting device, enrollment in a weight loss or exercise study or program, recent (< 1 year) or planned bariatric surgery

    7. Currently pregnant or pregnant in that last 6 months; breastfeeding currently or in the last 3 months

    8. Plans to be away from your desk for an extended period (>1 week) during the study period

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Pittsburgh Physical Activity and Weight Management Research Center Pittsburgh Pennsylvania United States 15216

    Sponsors and Collaborators

    • University of Pittsburgh
    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: Bethany Barone Gibbs, PhD, University of Pittsburgh

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Bethany Barone Gibbs, Assistant Professor, University of Pittsburgh
    ClinicalTrials.gov Identifier:
    NCT03307343
    Other Study ID Numbers:
    • R01HL134809
    • R01HL134809
    First Posted:
    Oct 11, 2017
    Last Update Posted:
    Aug 10, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Bethany Barone Gibbs, Assistant Professor, University of Pittsburgh
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 10, 2022